Solventum Corp

Insider Trading Arrangements and Policies

During the three months ended September 30, 2026, no director or officer of the Company adopted orterminated a“Rule 10b5-1 trading arrangement" or“non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

Shareholder Nominations

The Company’s definitive proxy statement for the 2026 annual meeting of shareholders of the Company, which was filed with the SEC on March 27, 2026, contained typographical errors in the section entitled “Questions & Answers About The Annual Meeting—What do I need to know to submit proposals and what are the deadlines to propose actions for consideration or to nominate individuals to serve as directors at the 2027 annual meeting of shareholders?” concerning the deadline for shareholders to bring nominations for directors or a proposal that a shareholder intends to present, but does not intend to have included in the Company's proxy statement and form of proxy at the Company’s 2027 annual meeting of shareholders. The corrected deadline is February 12, 2027, as set forth below.

Requirements for Director Nominees to Be Considered for Inclusion in our Proxy Materials (“Proxy Access”).

•Pursuant and subject to the proxy access provisions in our Bylaws, a shareholder or group of up to twenty shareholders, owning three percent or more of our outstanding common stock continuously for at least three years may nominate and include in our proxy materials director nominees constituting up to the greater of two directors or twenty percent of the number of directors then in office. Shareholder requests to include director nominees in our proxy statement and form of proxy relating to the 2027 annual meeting of shareholders must be delivered to our Corporate Secretary not earlier than January 15, 2027 and not later than the close of business on February 12, 2027.

•In addition, the notice must set forth the information required by our Bylaws with respect to each director nomination that a shareholder requests for inclusion in our proxy materials.

•Notice Requirements for Other Director Nominees or Shareholder Proposals to Be Brought Before the 2027 Annual Meeting of Shareholders.

•Notice of any director nomination or a proposal that a shareholder intends to present at the 2027 annual meeting of shareholders, but does not intend to have included in our proxy statement and form of proxy relating to the 2027 annual meeting of shareholders, must be delivered to our Corporate Secretary not earlier than the close of business on January 15, 2027 and not later than the close of business on February 12, 2027.

•In addition, the notice must set forth the information required by our Bylaws with respect to each director nomination or other proposal.

Availability of Information

Solventum’s website address is www.solventum.com. Investors and others should note that the Company announces material information to its investors using SEC filings, press releases, its investor relations website, public conference calls, webcasts and certain social media channels, including the following LinkedIn accounts: https://www.linkedin.com/in/bryanchanson/, and https://www.linkedin.com/in/wayde-mcmillan-9b233b33/. The Company uses these channels to communicate with investors, customers and the public about the Company, its products and other issues and for complying with its disclosure obligations under Regulation FD. The information on, or that may be accessed through, Solventum’s website is not incorporated by reference into this Quarterly Report on Form 10-Q and should not be considered a part of this Quarterly Report on Form 10-Q.